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Abstract
Background: Oxytocin administration, which may be of therapeutic value for individuals with social difficulties, is
likely to affect endogenous levels of other socially relevant hormones. However, to date, the effects of oxytocin
administration on endogenous hormones have only been examined in neurotypical individuals. The need to
consider multi-hormone interactions is particularly warranted in oxytocin trials for autism due to evidence of
irregularities in both oxytocin and sex steroid systems.
Methods: In this double-blind cross-over study, saliva samples were collected from 16 autistic and 29 neurotypical
women before and after intranasal administration of 24 IU oxytocin or placebo. Oestradiol, testosterone, and
oxytocin levels were quantified in saliva samples. Participants also completed the Autism-Spectrum Quotient (AQ)
and Empathy Quotient (EQ) questionnaires.
Results: Distinct patterns of change in testosterone and oestradiol levels pre- to-post-administration were observed
in autistic relative to neurotypical women (ANCOVA, p < 0.05 main effect of Group), controlling for sample collection time.
The mean percent change oestradiol was + 8.8% for the autism group and − 13.0% for the neurotypical group (t = 1.81,
p = 0.08), while the mean percent change testosterone was + 1.1% in the autism group and − 12.6% in the neurotypical
group (t = 1.26, p = 0.22). In the oxytocin condition, the mean percent change oestradiol was + 12.6% in the autism
group and − 6.9% in the neurotypical group (t = 1.78, p = 0.08), while the mean percent change testosterone was +
14.4% in the autism group and − 15.2% in the neurotypical group (t = 3.00, p = 0.006). Robust regression confirmed that
group differences in percent change hormone levels were not driven by a small number of influential individuals.
Baseline hormone levels did not differ between groups when considered individually. However, baseline testosterone
relative to oestradiol (T:E2 ratio) was higher in autistic women (p = 0.023, Cohen’s d = 0.63), and this ratio correlated
positively and negatively with AQ and EQ scores, respectively, in the combined sample.
Limitations: Further studies with larger and more diverse autistic sample are warranted to confirm these effects.
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Conclusions: This study provides the first evidence that oxytocin influences endogenous testosterone levels in autistic
individuals, with autistic women showing increases similar to previous reports of neurotypical men. These findings
highlight the need to consider sex steroid hormones as a variable in future oxytocin trials.
Keywords: Oxytocin, Autism, Sex steroids, Testosterone, Oestradiol, Salivary hormone levels, Autistic women
Background
The neuropeptide hormone oxytocin is known to modu-
late social behaviour across mammals including humans
[1]. For this reason, oxytocin has attracted interest for its
potential therapeutic applications in psychiatric condi-
tions characterised by challenges with social interactions
[2, 3]. Intranasal administration, a means of drug deliv-
ery to the brain [4], has become the standard method of
assessing the effect of a single hormone such as oxytocin
on behaviour. Despite recognition of the complexities of
the neuroendocrinology underlying human social behav-
iour and cognition [5], studies rarely consider the poten-
tial influence of other socially relevant hormones when
interpreting the results of oxytocin administration.
Short-term manipulation of oxytocin is likely to in-
fluence endogenous release of other hormones expected
to exert their own effects on social behaviour [6]. For ex-
ample, increased testosterone levels have been reported in
men [7, 8], but not in women [9], who received oxytocin
nasal spray versus placebo. Levels of arginine vasopressin,
a neurohormone closely related to oxytocin, were found
to increase in men and women following oxytocin admin-
istration [10]. Also in both sexes, the effects of oxytocin
administration on parenting-related behaviours were
found to depend on baseline endogenous testosterone
levels [8, 11]. Notably, oxytocin and testosterone adminis-
tration have shown opposing effects on various aspect of
social behaviour in neurotypical populations and show
opposite patterns of alteration in psychiatric conditions
such as autism and schizophrenia [12], although such
studies rarely assess multiple hormones within individuals.
While multi-hormone interplay and its relevance to
human social behaviour are yet to be fully elucidated, in-
teractions among oxytocin and sex steroid hormones are
well documented in animal research. Using in vitro re-
ceptor autoradiography, testosterone has been shown to
inhibit oxytocin receptor binding in the brains of male
mice [13]. Castration increases the number of oxytocin
immunoreactive neurons in the paraventricular nucleus
of male mice, while castration plus testosterone implants
decrease this number [14]. In rats, Leydig cells cultured
with oxytocin or an oxytocin agonist produce higher
levels of testosterone, and this increase in testosterone
production is mediated by the oxytocin receptor [15].
Oestradiol treatment in ovariectomised rats alters the
distribution of oxytocin immune-stained neurons and
oxytocin levels in brain regions including the lateral
septum, striatum, and amygdala [16]. Pre-treatment with
oestradiol enhances the anxiolytic effect of oxytocin
administration in female mice, possibly via enhance-
ment of oxytocin binding density [17]. The likelihood
of similar interactions between oxytocin and steroid
hormones in humans is supported by an in vitro study
of neuroblastoma cells demonstrating that the andro-
gen receptor mediates downregulation of oxytocin
gene expression [18]. Taken together, these studies
suggest a broadly inhibitory relationship between
testosterone and oxytocin and a broadly synergistic
relationship between oestrogens and oxytocin, although
these relationships may be further complicated by sex
differences in steroid hormone levels and oxytocin
receptor systems in the brain [19].
People with autism spectrum conditions (henceforth
autism) are an important clinical group to inform the
exploration of the interplay among hormones and its ef-
fects on social behaviour. The social and communication
challenges that characterise autism [20] have been asso-
ciated with lower endogenous oxytocin levels in autistic
children [21–23]. Furthermore, several lines of evidence
support that elevation of sex steroid hormones, includ-
ing androgens and oestrogens, contributes to the like-
lihood of autism [24–27]. Nevertheless, interactions with
sex steroid hormones have not been considered in pre-
vious trials assessing the effects of oxytocin administration
on social cognition in autistic individuals [28].
To date, the effects of oxytocin administration on
endogenous steroid hormone levels have been exam-
ined in neurotypical individuals. Weisman et al. [8] re-
ported alterations in fathers’ salivary testosterone
levels after oxytocin administration relative to placebo.
Gossen et al. [7] reported alterations in serum testos-
terone and progesterone, but not in oestradiol, in neu-
rotypical men after oxytocin administration. Increases
in testosterone levels after central oxytocin administra-
tion have also been reported in male squirrel monkeys
[29]. In a study of women, Holtfrerich et al. [9] found
that post-administration salivary testosterone levels
did not differ between oxytocin and control groups.
However, whether changes in steroid hormone levels
occur in individuals with an autism diagnosis following
oxytocin administration remains untested. To better
assess oxytocin’s potential as a therapeutic agent in
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autism, further study of the interplay among oxytocin,
other socially relevant hormones, and biological sex is
warranted.
To address these questions, we analysed salivary hor-
mone levels in autistic and neurotypical women before
and after intranasal administration of oxytocin or placebo.
The aims of this study were threefold. The first is to assess
changes in endogenous testosterone and oestradiol after
oxytocin administration and whether these changes
differed with autism diagnosis. Salivary oxytocin was also
measured, which allowed us to confirm the manipulation
of oxytocin and, given recent evidence that pre-treatment
oxytocin level influences response to oxytocin in autistic
children [30], include baseline oxytocin in the analyses.
Second, the data were used to compare baseline hormone
levels between autistic and neurotypical women. The third
aim was to explore relationships between baseline hor-
mone levels and two psychological variables linked to aut-
ism, namely the Autism-Spectrum Quotient (AQ) [31]
and the Empathy Quotient (EQ) [32]. Given the literature
on interactions between oxytocin and sex steroids, as well
as the possibility of a hypermasculinised phenotype in aut-
ism [33, 34], we predict that oxytocin administration will
promote testosterone decreases in neurotypical women
but testosterone increases in autistic women—similar to
previous reports for neurotypical men [7, 8]. Further, mo-
tivated by recent work reporting a role of oestrogens in
autism [27], we predict a higher testosterone relative to
oestradiol (T:E2 ratio) in autistic women and/or women
with higher levels of autistic-like traits.
Methods
Participants
A total of 45 women aged 18–50 years participated in
this study. Of these, 16 had a diagnosis of autistic dis-
order/childhood autism or Asperger’s disorder/syn-
drome based on DSM-IV or ICD-10 criteria (autism
group), and 29 were neurotypical (neurotypical group).
The two groups did not differ significantly in age or full
IQ (Table 1). No participant had a history of psychotic
disorders or substance use disorder; any genetic syndrome
associated with autism; intellectual disability; epilepsy;
hyperkinetic disorder; Tourette’s syndrome; or current or
past use of anti-psychotic, glucocorticoid, psychostimulant,
or antihypertensive drugs. Use of hormonal contraceptives
and anti-depressants was permitted, as a significant propor-
tion of the study population was expected to be taking such
medication.
Experimental design
Data were collected as part of a larger neuroimaging
study [35] with a double-blind, placebo-controlled,
within-subjects crossover design. Each participant was
randomly assigned to receive placebo or oxytocin first.
Normally-cycling participants self-reported date of last
menstruation and were scheduled to participate during
the early follicular stage in an effort to minimise differ-
ences in hormone levels between sessions. For partici-
pants taking hormonal contraceptives, the second
session was scheduled a minimum of 1 week later to
ensure complete wash-out. For most participants, the
Table 1 Demographic characteristics, psychological questionnaire scores, and baseline hormone levels in the autism and
neurotypical groups
Autism Neurotypical p-value Cohen’s d
N 16 29
Demographics
Age (years) 29.9 ± 8.4 27.2 ± 8.1 0.31 0.33
Full-IQ1 121.2 ± 16.4 114.6 ± 14.3 0.19 0.44
Hormonal contraceptive use (n) 0 8
Psychological variables
Autism-Spectrum Quotient (AQ) 37.1 ± 5.1 14.1 ± 7.5 < 0.01** 3.4
Empathy Quotient (EQ) 20.7 ± 11.7 54.6 ± 14.0 < 0.01** − 2.5
Baseline hormone levels2
Baseline oestradiol (pg/ml) 1.0 ± 0.3 1.2 ± 0.5 0.055 − 0.54
Baseline testosterone (pg/ml) 70.3 ± 24.9 66.4 ± 22.0 0.60 0.17
T:E2 ratio3 0.39 ± 0.63 − 0.22 ± 1.1 0.023 * 0.63
Baseline oxytocin (pg/ml) 3.1 ± 0.5 2.8 ± 0.6 0.064 0.57
Values are mean ± SD, unless otherwise specified
*p < 0.05, **p < 0.01
1Wechsler Abbreviated Scale of Intelligence
2Baseline hormone levels were calculated as the mean of the two pre-administration samples collected per participant
3Log-transformed and then normalised to have mean of 0 and standard deviation of 1
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interval between sessions was 7–15 days; the maximum
interval between sessions was 51 days.
Before participating in the experiment, participants
underwent a short health screening (comprising heart
and blood pressure measurement, inquiry about allergies,
and pregnancy test) by a trained clinician and were
deemed fit to participate. Participants received either a
dose of 24 IU oxytocin (Syntocinon, Novartis, Switzerland)
or placebo (prepared by Newcastle Specials Pharmacy
Production Unit) and were instructed to self-administer
three puffs to each nostril. Following administration, par-
ticipants rested for 20min before completing a neuroim-
aging session lasting approximately 1 h. The neuroimaging
session comprised a resting state scan and three fMRI
tasks. Participants completed the same series of neuro-
imaging tasks in each session.
Psychological self-report questionnaires were completed
in advance of the experiment. The Autism-Spectrum
Quotient (AQ) was used to quantify autistic-like traits
[31], and the Empathy Quotient (EQ) was used to quantify
the cognitive and affective domains of empathy [32].
Saliva collection
Participants were instructed to refrain from consuming
caffeinated beverages the day of the experiment and to
refrain from consuming alcohol for 24 h prior to testing.
Saliva samples were collected at three timepoints: (1)
baseline (40 ± 20 min before administration), (2) shortly
after intranasal administration of placebo or oxytocin (6
± 4min post-administration), and (3) after completion
of the neuroimaging session described above (96 ± 19
min post-administration). The average interval between
time 1 and 2 was thus 46 min, while the average interval
between times 1 and 3 was 136 min. In total, six saliva
samples (three in the oxytocin condition, three in the
placebo condition) were collected per participant. Saliva
samples were collected by passive drool and frozen
immediately at − 80 °C until analysis.
Salivary hormone analysis
Salivary hormone level analysis is a minimally invasive
method commonly used in behavioural research [36].
Salivary oestradiol and testosterone were analysed using
commercially-available enzyme-linked immunosorbent
assay (ELISA) kits designed specifically for use with
saliva (Salimetrics, USA). Assays were performed by the
NIHR Cambridge Biomedical Research Centre, Core
Biochemical Assay Laboratory. Oxytocin was quantified
using a highly sensitive and specific radioimmunoassay
(RIAgnosis, Germany); salivary oxytocin measured by
this method correlates with oxytocin in cerebrospinal
fluid [37]. Intra- and inter-assay variability was < 15%
for oestradiol, < 12% for testosterone, and < 10% for
oxytocin.
For two samples, the obtained oestradiol concentration
was below the detection limit of the kit (< 0.1 pg/ml); as
oestradiol values for other samples from those individ-
uals were well above the detection limit, the low values
were deemed invalid measurements and excluded from
analysis. One baseline testosterone value and one base-
line oestradiol value were identified as outliers (± 3
standard deviation (SD) of the mean). As these measure-
ments appeared to be valid (i.e. other samples from the
participant were at the higher range), these two values
were winsorised (set at the highest value that was not an
outlier) and included in the analysis. The number of
samples used in the analyses was thus 90 per time point
per hormone, with the exception of 88 samples for time
point 2 for oestradiol.
Baseline hormone levels were calculated as the mean
of the two samples collected before administration per
participant. To assess the balance of sex steroid hor-
mones, in line with previous research assessing multiple
sex steroids in autism and published recommendations
[27, 38], the baseline testosterone to baseline oestradiol
ratio (T:E2 ratio) was computed as log(baseline testoster-
one) − log(baseline oestradiol) and then normalised to
have a mean of 0 and standard deviation of 1. To ex-
plore post-administration changes in hormone levels,
the percent change from time point 1 (to time points
2 (~ 6 min post-administration) and 3 (~ 96 min
post-administration) was calculated as (final − initial)/
initial).
Statistical analysis
Data are reported as mean and standard deviation.
Baseline hormone levels and psychological variables
were compared between the autism and neurotypical
groups using Welch’s t test. Changes in hormone
levels over time within individuals were compared
using paired t tests. Pre- to post-administration
percent change in hormone levels between groups
(autism or neurotypical) and drug condition (oxytocin
or placebo) were assessed by analysis of covariance
(ANCOVA), controlling for collection time of the
baseline saliva sample and the interval (in minutes)
between the initial and final sample. Because linear
regression can be sensitive to small datasets, robust
regression using iterated re-weighted least squares
was also performed. Robust regression attempts to
ignore or down-weight unusual data [39], offering
further support that results are not driven by a small
number of highly influential datapoints. Statistical
analyses were performed using R version 3.6.2 [40].
Effect sizes were calculated using the “effsize” pack-
age, and the “MASS” package was used for robust
regression.
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Results
Participant characteristics and baseline hormone levels
A comparison of demographic characteristics, question-
naire scores, and baseline hormone levels between the
autism and neurotypical groups is presented in Table 1.
The two groups did not differ in terms of age, IQ, base-
line oestradiol, baseline testosterone, or baseline oxyto-
cin. The T:E2 ratio, however, was significantly different,
with autistic women showing greater testosterone rela-
tive to oestrogen and neurotypical women showing the
opposite pattern. Psychological variables also differed
between groups in the expected direction, with autistic
women having substantially higher AQ scores and lower
EQ scores than neurotypical women. Baseline hormone
levels were not related to age (r < 0.10, p > 0.50, all tests)
and did not differ significantly between sessions (Welch’s
t test, p > 0.45 all tests), or with hormonal contraceptive
use (Welch’s t test, p > 0.11 all tests). Exclusion of
the eight neurotypical women who reported taking
hormonal contraceptives did not change these results
(Supplementary Table S1).
The relationships between baseline hormone levels
and psychological traits are presented in Fig. 1. In the
overall sample, greater baseline testosterone relative to
oestradiol was positively correlated with AQ score (r =
0.36, p = 0.017), and negatively correlated with EQ score
(r = − 0.35, p = 0.02). Baseline oxytocin showed a trend
of a positive correlation with AQ score (r = 0.27, p =
0.067) but no relationship with EQ score (r = − 0.12, p =
0.45). Similar patterns were present when correlations
were determined separately for the two groups (autism:
r = 0.22, p = 0.44 for AQ and T:E2; r = − 0.44, p = 0.10
for EQ and T:E2; r = 0.51, p = 0.05 for oxytocin and
AQ; r = 0.11, p = 0.69 for oxytocin and EQ; neurotypi-
cal: r = 0.25, p = 0.24 for AQ and T:E2; r = − 0.14, p =
0.43 for EQ and T:E2; r = − 0.05., p = 0.80 for oxytocin
and AQ; r = 0.18, p = 0.35 for oxytocin and EQ),
although statistical significance was not achieved with
the smaller sample sizes.
Pre- to post-administration changes in salivary hormone
levels
Figure 2 presents the mean oestradiol and testosterone
levels at each time point separated by group (autism and
neurotypical) and drug condition (oxytocin and placebo)
(see Supplementary Figures S2-S5 for individual level
hormone levels). For the combined participants, paired tests
indicated small but significant decreases (oestradiol: time 1
vs time 2, mean change of − 0.16 pg/ml, p < 0.001, time 1
vs time 3, mean change of − 0.14 pg/ml, p = 0.01;
testosterone: time 1 vs time 2, mean change of − 10.1 pg/ml,
p < 0.001, time 1 vs time 3, mean change of − 7.8 pg/ml,
p < 0.01). Comparison of oxytocin levels across the
three time points between drug conditions confirmed the
effects of the manipulation (Supplementary Table S2).
Figure 3 presents the mean percent change oestradiol
and testosterone from time point 1 to 3 separated by
group (autism and neurotypical) and drug condition
(oxytocin and placebo). ANCOVA revealed a significant
group difference in percent change testosterone (F(1, 79)
= 6.5, p = 0.01) and percent change oestradiol (F(1,79) =
4.3, p = 0.04), controlling for collection time of the base-
line sample and the interval between time points (see
Supplementary Tables S3 and S4 for full ANCOVA
table). In the placebo condition, the mean percent
change oestradiol was + 8.8% for the autism group and
− 13.0% for the neurotypical group (t = 1.81, p = 0.08),
while the mean percent change testosterone was + 1.1%
in the autism group and − 12.6% in the neurotypical
group (t = 1.26, p = 0.22). In the oxytocin condition, the
mean percent change oestradiol was + 12.6% in the
autism group and − 6.9% in the neurotypical group (t =
1.78, p = 0.08), while the mean percent change testoster-
one was + 14.4% in the autism group and − 15.2% in the
neurotypical group (t = 3.00, p = 0.006, 95% confidence
interval of difference = 9.3–50%). Exclusion of the eight
neurotypical women taking hormonal contraceptives did
not substantially change the results (Supplementary
Tables S5, S6), nor was there an effect of baseline oxyto-
cin when it was included in the analyses (Supplementary
Tables S7, S8).
As the differences in percent change oestradiol be-
tween autistic and neurotypical women were not signifi-
cant in the post hoc tests, they were not explored
further. Thus, robust regression was performed only for
analysis of percent change testosterone to ensure that
the significant group difference was not driven by
hormone level changes for a small number of highly in-
fluential individuals. Four observations (3 autistic partici-
pants, 1 neurotypical participant) were substantially
down-weighted (< 0.60, Huber weight), which did not
substantially change the statistics supporting the group
difference. As further support for this group difference,
two-sample tests for equality of proportions with con-
tinuity correction were performed. After oxytocin, tes-
tosterone levels increased in 11 of 16 autistic women but
in only 8 of 29 neurotypical women (χ2 = 5.6, p = 0.018).
By contrast, after placebo, the proportions of women
showing increased testosterone levels between the two
groups were nearly identical (5/16 autistic, 9/29 neuro-
typical, χ2 = 0.0, p = 1).
Discussion
In the present study, we sought to identify interactions
between oxytocin and steroid hormones that could po-
tentially influence the outcomes of oxytocin administra-
tion in experimental and clinical settings. Given the
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underrepresentation of women in both autism research
and endocrinology research, this work has made several
important contributions to a sparse literature. First, on
average, women in our study showed small but signifi-
cant decreases in both salivary oestradiol and testoster-
one levels over time, which is consistent with expected
diurnal rhythms of sex steroid hormone [41]. However,
post hoc tests revealed that decreases in hormone levels
over time were limited to neurotypical women, with
autistic women instead showing average increases. Oxy-
tocin enhanced the between-group difference in percent
change testosterone, with the majority of autistic women
(11 of 16) showing an increase and the majority of
neurotypical women (21 of 29) showing a decrease over
time. The pattern for autistic women is in line with the
findings by Gossen et al. [7] that men’s testosterone
levels increased over a time course of 210 min after oxy-
tocin administration. In a study by Weisman et al. [8] on
the effects of oxytocin administration on parent-child
interactions, fathers’ testosterone levels decreased over
time, but those who received oxytocin had significantly
higher testosterone levels 40, 60, and 80 min after
Fig. 1 Correlations between hormonal and psychological variables: a T:E2 ratio (log-transformed and normalised ratio of baseline testosterone to
oestradiol) and Autism-Spectrum Quotient (AQ) score; b ratio of baseline testosterone to oestradiol (log-transformed and normalised T:E2 ratio)
and Empathy Quotient (EQ) score; c baseline oxytocin and AQ score; and d baseline oxytocin and EQ score. Regression line is indicated in black
with 95% confidence intervals shaded in grey. Autistic and neurotypical women participants are indicated by darker blue circles and lighter
yellow triangles, respectively
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administration relative to the placebo condition. The
pattern observed in autistic women is consistent with
the idea of a masculinised phenotype [33, 34], as they
showed sex hormone responses to oxytocin distinct from
those of the neurotypical women in our study and more
like the responses previously reported for neurotypical
males. In the neurotypical women in our study, we see
no evidence that oxytocin elevated testosterone levels
relative to placebo—rather, testosterone levels were
slightly higher under the placebo condition (time 2 56.4
± 18.9 placebo, 52.7 ± 17.3 oxytocin; time 3 54.7 ± 15.6
placebo, 52.4 ± 16.2 oxytocin). In line with our findings
for neurotypical women, Holtfrerich et al. [9] reported a
small decrease in salivary testosterone for 29 women
administered 24 IU oxytocin (oxytocin group: baseline =
25.05 ± 20.9 pg/ml, post-administration = 23.28 ± 12.7 pg/
ml). Although the authors state that post-administration
testosterone levels did not differ significantly between
oxytocin and placebo groups, the control group comprised
28 different women with a lower baseline testosterone level
(see Supplementary material of (9)).
In the present study, as testosterone levels tended to
increase under both the placebo and oxytocin conditions
in autistic women, this begs the question of why.
Endogenous testosterone levels are reported to increase in
contexts related to competition and mating [42], neither
of which is applicable to our experimental context. One
possibility is that autistic women experienced more stress
during neuroimaging, as elevated testosterone levels have
been reported in response to both social and physical
stress [43]. Oxytocin—which is generally considered to
have anxiolytic effects [44]—is thought to influence stress
response via sex-specific effects on hypothalamic-
pituitary-adrenal axis hormones [45]. However, in autism,
oxytocin may enhance stress response, as shown in a ro-
dent model of oxytocin-deficient female mice [46]. Grillon
Fig. 2 Mean salivary oestradiol levels (upper panels) and testosterone (lower panels) under the placebo and oxytocin conditions across the three
measurement points (Time point 1 = before administration, 2 = ~ 6 min post-administration, 3 = ~96min post-administration). Error bars indicate
the standard error of the mean. From left to right, the panels show: (i) hormone levels separated by drug condition for all participants; (ii) hormone
levels separated by drug condition for the autism group; and (iii) hormone levels separated by drug condition for the neurotypical group
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et al. [47] demonstrated that oxytocin can increase anxiety
in humans, specifically defensive response to an unpre-
dictable threat. Therefore, it is possible that testosterone
increase in our autistic participants was related to stress
and that oxytocin administration amplified stress reactiv-
ity. If oxytocin has anxiogenic effects in certain individ-
uals, which may be indicated by increases in endogenous
testosterone, they are unlikely to benefit from therapeutic
interventions involving oxytocin.
Furthermore, our data presented a rare opportunity to
compare hormone levels between autistic and neurotypi-
cal adult women. In our sample, we found no significant
differences in baseline oestradiol, testosterone, or oxyto-
cin when considered individually. The findings from pre-
vious studies comparing hormone levels between autistic
and neurotypical adults are mixed. Ruta et al. [26] and
Xu et al. [48] reported no difference in oestradiol levels
in blood between a mixed sex sample of autistic adults
(33 men, 25 women) vs. controls and 61 mothers of aut-
istic children vs. control mothers, respectively. Ruta
et al. [26] further reported no difference in testosterone
or the testosterone to oestradiol ratio between autistic
and neurotypical individuals. By contrast, Schwarz et al.
[49] reported elevated testosterone levels in 23 women
with Asperger’s syndrome relative to controls, while Xu
et al. found elevated testosterone levels and reduced
plasma oxytocin levels in mothers of autistic children
relative to mothers of typically developing children [48].
While our study has the advantage of comparing hor-
mone levels in two saliva samples, our study was under-
powered to detect small differences due to the small
sample size and high variability in salivary hormone
measures.
Recent findings that medical conditions associated
with elevated testosterone, such as polycystic ovary syn-
drome, are more common in autistic women [25, 50]
supports potential roles of dysregulation of sex steroid
hormone systems in autism, even if such differences are
not reliably found in blood or saliva samples. Although
it did not meet the threshold for statistical significance,
the difference in testosterone levels between the autistic
and neurotypical women in our study was in the
predicted direction (see Table 1).
Interestingly, the ratio of testosterone to oestradiol dif-
fered between autistic and neurotypical women and was
positively correlated with autistic-like traits (AQ score)
and negatively correlated with self-reported empathy
(EQ score) in our combined sample. Although the corre-
lations are modest, they are broadly consistent with pre-
vious reports of associations between hormone measures
and social traits. Prenatal testosterone levels, as
measured in amniotic fluid, are positively and negatively
correlated, respectively, with scores on the childhood
versions of the AQ and EQ [51]. Adult women with
Fig. 3. Density plots of percent change hormone levels from time 1 to 3 between autistic (indicated in blue) and neurotypical (indicated in
yellow) groups: a percent change oestradiol under placebo condition; b percent change oestradiol under oxytocin condition; c percent change
testosterone under placebo condition; d percent change testosterone under oxytocin condition. Dashed lines indicate the means for each group
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elevated testosterone levels due to congenital adrenal
hyperplasia are reported to have higher levels of autistic-
like traits than controls [52], whereas girls with lower
testosterone levels scored higher on cognitive empathy
than girls with higher testosterone [53]. The aforemen-
tioned studies—like the present study—are based on
small samples and thus warrant replication. Recent stud-
ies involving larger neurotypical samples have reported
no relationship between salivary testosterone and AQ
score in 67 young men [54] and no relationship between
testosterone or oxytocin and AQ or EQ in 173 adults
(94 women) [55]. Nevertheless, the findings of the
present study suggest that consideration of multiple
hormones within one pathway—such as oestradiol and
testosterone—may better reflect relationships between
hormone levels and social variables of relevance to
autism. Indeed, a recent study has provided the first evi-
dence that elevation of prenatal oestrogens contributes
to the likelihood of autism in boys [27]. Whether pre-
natal oestrogens, or the ratio of androgens to oestrogens,
contribute to autism likelihood in girls is yet to be
tested.
Limitations
This study has several limitations. First, as this study uti-
lised saliva samples collected from participants during a
neuroimaging experiment, participants were scheduled
based on scanner availability rather than within a narrow
time window typically used to assess hormones. Two
time-related covariates were included in the analyses to
account for expected diurnal variation. While decreases
in testosterone levels later in the day are well-established
in men, time of day may not affect salivary testosterone
levels in women [56]. In our data, we saw no evidence of
decreased hormone levels later in the day (see Figure S1).
The menstrual cycle may also influence hormone levels,
and participants were scheduled to participate in the ex-
periment during the follicular stage to minimise differences
between sessions. As menstrual stage was self-reported, this
information may be unreliable. However, stage of menstrual
cycle is not expected to greatly influence testosterone levels
[56]. Second, due to the intervening neuroimaging session,
saliva samples were limited to two time points post-
administration. The optimal sampling time to test interac-
tions between oxytocin and sex steroids is unclear. In previ-
ous studies of men [7, 8], elevated testosterone levels were
reported 40 to 210min after oxytocin administration. Our
main measurement point (~ 96min post-administration)
was in the middle of this range. It is possible that the differ-
ence in testosterone levels between autistic and neurotypi-
cal women following oxytocin administration could vary
with sampling time. Third, we cannot rule out the possibil-
ity that the neuroimaging experiment influenced hormone
levels. However, as the same series of neuroimaging tasks
was performed in each session, the effects of the task—if
any—should be consistent across sessions. Lastly, as this is
the first study to assess post-oxytocin administration hor-
mone changes in autistic individuals and the sample size
was relatively small, further studies are needed to confirm
our main finding that neurotypical and autistic women
show opposite patterns of sex steroid hormone changes in
response to oxytocin. The effect of oxytocin administration
on hormone levels in autistic men also warrants investiga-
tion. Future studies should strive to include individuals with
more diverse phenotypes [57], as our autistic sample would
be considered “high-functioning” and is not necessarily
representative of the general autism phenotype.
Notably, not all autistic women showed increased tes-
tosterone levels and not all neurotypical women showed
decreased testosterone levels after oxytocin adminis-
tration. Whether individual changes in endogenous
hormone levels are related to the effects of oxytocin on
behaviour—particularly the social behaviours that oxyto-
cin administration aims to enhance in clinical popula-
tions—is yet to be tested. In a recent oxytocin trial in
autistic children, Parker et al. [30] found that low pre-
treatment baseline oxytocin levels were predictive of
improvement in social functioning with oxytocin. In an
oxytocin administration study of neurotypical women,
oxytocin administration was found to decrease response
time to face stimuli but only among women with high
endogenous testosterone levels [11]. Given the inconsist-
ent findings of oxytocin clinical trials to date [58, 59],
the possibility that baseline sex steroids or oxytocin-
associated changes in sex steroids could serve as a bio-
marker of response may help to identify autistic people
expected to benefit most from interventions involving
oxytocin.
Conclusions
This study provides further evidence that a single dose
of oxytocin influences endogenous sex steroid levels,
providing the first evidence of this effect in autistic in-
dividuals. Using a within-subjects, placebo-controlled
design, opposite directional changes in salivary testos-
terone levels were found between autistic and neuroty-
pical women, with autistic women showing increases in
salivary testosterone levels, which is contra the ex-
pected diurnal pattern and consistent with previous re-
ports in neurotypical men. Furthermore, we found that
the ratio of testosterone to oestradiol differed between
autistic and neurotypical women, and that this ratio
correlated with self-reported autistic-like traits and em-
pathy, consistent with predictions based on the social
neuroendocrinology literature. Taken together, these
findings highlight the need to consider current sex ster-
oid hormone levels as a variable in future oxytocin
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trials in autism and to consider multiple sex steroids in
studies of hormone system differences in autism.
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